Migrastatic therapy as a potential game-changer in adaptive cancer treatment
Katharina Schneider (Maastricht University)
Louise Spekking (TU Delft - Information and Communication Technology)
Sepinoud Azimi (TU Delft - Information and Communication Technology)
Barbora Peltanová (Charles University)
Daniel Rösel (Charles University)
Joel S. Brown (Lee Moffitt Cancer Center and Research Institute)
Robert A. Gatenby (Lee Moffitt Cancer Center and Research Institute)
Jan Brábek (Charles University)
Kateřina Staňková (TU Delft - Transport and Logistics)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Adaptive therapy, which anticipates and counters the evolution of resistance in cancer cells, has gained significant traction, especially following the success of the Zhang et al.'s protocol in treating metastatic castrate-resistant prostate cancer. While several adaptive therapies have now advanced to clinical trials, none currently incorporates migrastatics, i.e. treatments designed to inhibit cancer cell metastasis. In this study, we propose integrating migrastatics into adaptive therapy protocols and evaluate its potential benefits through a spatial game-theoretic model. Our results demonstrate that combining adaptive therapy with migrastatics effectively delays the onset of metastases and reduces both the number and size of metastases in most cancer scenarios analyzed. Including migrastatics to adaptive therapy not only extends the time to the first metastasis, but also enhances the overall efficacy of adaptive therapies. Our findings suggest a promising new direction for cancer treatment, where adaptive therapy, in combination with migrastatic agents, can target both the evolution of resistance and the metastatic spread of cancer cells.
help_outline